Ethicon Endo-Surgery launches energy delivery devices at the 95th ACS Annual Clinical Congress

Ethicon Endo-Surgery, Inc., today unveiled its broad portfolio of energy delivery devices at the 95th Annual Clinical Congress of the American College of Surgeons (ACS).

The complementary energy technologies of worldwide leading HARMONIC® ultrasonic and ENSEAL® advanced bipolar devices provide surgeons with multiple energy delivery options that provide superior energy application for desired tissue effects to meet specific surgical needs across multiple surgical specialties. Ethicon Endo-Surgery acquired the ENSEAL® technology in October 2008; the ACS Annual Clinical Congress marks the full integration of the ENSEAL® product line into the Ethicon Endo-Surgery energy portfolio.

"I believe energy is the future of surgery, which is why we're seeing such significant advances in both bipolar and ultrasonic energy, which enhance the experience of surgeons and patients alike," said Michael J. Stamos, MD, FACS, FASCRS, chief, Division of Colon & Rectal Surgery, Department of Surgery, University of California, Irvine. "Since each patient case is unique, it is imperative to understand the distinctive attributes of each different energy technology. It also is critical to have the confidence and flexibility to choose the right modality to achieve optimal outcomes for both patients and for surgeons in terms of greater precision and control, maximized surgical efficiency and best tissue effect."

As energy delivery device options have evolved, they have enabled more efficient and minimally invasive surgical techniques. Ethicon Endo-Surgery, originally with HARMONIC® technology and now ENSEAL®, has led this evolution of surgery by working directly with surgeons to develop innovations, enabling greater functionality, controlled tissue sealing, and minimization of tissue trauma.

With its bipolar technology, ENSEAL® offers superior control in large vessel sealing for surgical procedures in general, colorectal, gynecology, and urology where minimal tissue damage is critical. Pre-clinical studies have shown ENSEAL® laparoscopic and open devices contain energy spread and are faster at sealing and transecting than competitive devices, while offering exceptional large vessel sealing (up to and including 7mm blood vessels).

As the leading ultrasonic cutting and coagulating surgical device used in more than 8 million surgical procedures worldwide since 1995, HARMONIC® allows precise application of ultrasonic energy in advanced laparoscopic and open procedures, and minimizes adjacent tissue damage to the patient. These devices are versatile and help the surgeon perform multiple surgical tasks with a single device that can lead to overall efficiency improvement over traditional techniques. HARMONIC® is indicated for multiple specialties and surgeries, including laparoscopic and open technique procedures within general, colorectal, gynecologic and urologic procedures, and often is credited with being the first device to enable some advanced laparoscopic procedures that general surgeons perform today.

"An increasing number of surgeons are applying the new technologies as standard of care for both laparoscopic and open procedures," said Kevin Lobo, worldwide president, Ethicon Endo-Surgery. "By offering both an ultrasonic and advanced bipolar technology, Ethicon Endo-Surgery delivers options to meet the needs of traditional and emerging surgical techniques."

Source:

Ethicon Endo-Surgery, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
PDX engraftment predicts high recurrence and poor survival in triple-negative breast cancer